SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis.
Dr. Leonardo Riella was interviewed by our Social Media Editor, Macey Levan, about the recent publication in Transplantation.
Kidney transplant (KT) recipients experience high rates of cardiovascular disease, allograft dysfunction, and diabetes, negatively impacting long-term outcomes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and kidney benefits in non-KT recipients, but evidence in KT recipients remains limited. This systematic review and meta-analysis provide updated evidence on the efficacy and safety of SGLT2i and GLP-1RAs on KT recipients.
Original Article:
https://journals.lww.com/transplantjournal/fulltext/9900/sglt2_inhibitors_and_glp_1_receptor_agonists_in.1154.aspx
–
About the Journal
The official Journal of The Transplantation Society. Transplantation (https://transplantjournal.com) is published monthly and is a highly cited and influential journal in the field, with more than 25,000 citations per year.
–
The Transplantation Society – Learn more about our journla:
https://tts.org/journal/transplantation-journal
